Cocrystal Pharma, Inc.COCPNASDAQ
Loading
Year-over-year research & development expense growth
Percentile
P44
Within normal range
vs 5Y Ago
-2.9x
Contraction
Streak
3 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q3 2025 | -14.97% |
| Q2 2025 | -17.50% |
| Q1 2025 | -33.24% |
| Q4 2024 | -37.17% |
| Q3 2024 | -24.74% |
| Q2 2024 | 46.03% |
| Q1 2024 | -30.86% |
| Q4 2023 | 1.74% |
| Q3 2023 | 49.73% |
| Q2 2023 | -28.31% |
| Q1 2023 | 18.86% |
| Q4 2022 | -15.11% |
| Q3 2022 | 64.00% |
| Q2 2022 | -17.79% |
| Q1 2022 | 30.07% |
| Q4 2021 | 4.89% |
| Q3 2021 | -17.68% |
| Q2 2021 | 62.14% |
| Q1 2021 | 125.93% |
| Q4 2020 | -66.39% |
| Q3 2020 | 5.11% |
| Q2 2020 | 54.01% |
| Q1 2020 | 33.92% |
| Q4 2019 | -11.05% |
| Q3 2019 | -1.28% |
| Q2 2019 | 24.26% |
| Q1 2019 | -98.41% |
| Q4 2018 | 3656.51% |
| Q3 2018 | 31.10% |
| Q2 2018 | 27.59% |
| Q1 2018 | -20.56% |
| Q4 2017 | -20.75% |
| Q3 2017 | 11.00% |
| Q2 2017 | -39.40% |
| Q1 2017 | -97.79% |
| Q4 2016 | 4385.24% |
| Q3 2016 | -11.61% |
| Q2 2016 | -29.14% |
| Q1 2016 | -91.95% |
| Q4 2015 | 1806.75% |